By the Top Tier Newswire AI Desk · August 27, 2026 at 12:27 AM ET · reviewed against 14 wire stories
SUMMIT THERAPEUTICS (SMMT) is up +6.51% in the latest session. Our newswire has captured 14 stories on SMMT across 11 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SMMT stock is up today
SUMMIT THERAPEUTICS (SMMT) shares rose 6.51% to $14.23 in a session driven by positive developments in its partner Akeso’s phase 3 trial for the drug ivonescimab. The trial showed ivonescimab outperformed AstraZeneca’s Imfinzi in treating advanced biliary tract cancer. This result has increased investor confidence in the drug’s potential and the company’s broader pipeline.
What Happened
Akeso, Summit Therapeutics’ partner, reported that ivonescimab plus chemotherapy achieved statistically significant overall survival in patients with advanced biliary tract cancer. The drug demonstrated a survival benefit over Imfinzi, a well-established competitor. Summit Therapeutics holds the rights to develop and commercialize ivonescimab outside of China. The positive phase 3 results have enhanced the credibility of Summit’s global lung cancer trials and signaled progress for its key drug candidate.
Guggenheim analysts noted that Akeso’s results could strengthen Summit’s position in the bispecific immunotherapy space. Additionally, Canaccord initiated coverage of Summit with a Buy rating, and HC Wainwright & Co. reiterates a Neutral stance. Summit also filed an 8-K with the SEC, disclosing the event and related financial statements. Recent insider transactions also reflect confidence, with multiple executives purchasing shares totaling $103.6 million in the last 90 days.
What The Data Shows
Over the past eight sessions, SMMT shares have risen 11.0%, from $12.78 to $14.18. The stock is currently trading within its 52-week range of $12.07 to $30.05. The 52-week tape showed 4 fresh 52-week highs and 10 fresh 52-week lows on August 27. The stock traded with above-average volume, though specific volume figures are not available. The company remains unprofitable with a trailing twelve-month revenue decline of 100.0% and an EPS of -1.12. Despite these fundamentals, the recent positive data and analyst upgrades have driven a short-term rally.
What To Watch
Investors should monitor upcoming developments in the ivonescimab pipeline and any further analyst coverage. Summit Therapeutics has no earnings date scheduled in the immediate future, but continued progress in clinical trials could influence investor sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · Aug 27 session (5-min) · +0.70% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 14 stories · 63/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
17d agoSCMPBULLISH 67Product/PR
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer. The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage. The Chinese trial tested ivonescimab and chemotherapy…
17d agoSeeking AlphaBULLISH 63Analyst
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)
Summit Therapeutics is upgraded to Buy as sentiment bottoms and ivonescimab catalysts near; assess upside vs. cash burn. Click for this SMMT update.
17d agoStocktwits NewsBULLISH 67Product/PR
Summit’s Global Lung Cancer Trials Gain Credibility After Akeso’s Phase 3 Data, Says Guggenheim
Akeso reported positive late-stage data for Ivonescimab, a drug that Summit Therapeutics holds the rights to develop and sell outside China.
17d agoMarketChameleonBULLISH 73Product/PR
Ivonescimab Shows Significant Survival Benefit Over Durvalumab in Advanced Biliary Tract Cancer—What This Means for Summit Therapeutics’ Pipeline
August 26, 2026
Summit Therapeutics’ partner Akeso reported that ivonescimab plus chemotherapy achieved statistically significant overall survival in advanced biliary tract cancer, marking a pivotal moment in bispecific immunotherapy development. This article breaks down what the topline results mean for Summit’s clinical strategy and future prospects.
17d agoThe FlyBULLISH 61Analyst
Summit Royalties initiated with a Buy at Canaccord
17d agoTipRanksBULLISH 73Product/PR
Summit Therapeutics’ Ivonescimab Shows Phase III Survival Benefit
The latest announcement is out from Summit Therapeutics ( ($SMMT) ). On August 25, 2026, Summit Therapeutics highlighted positive topline results reported by its pa...
17d agoSEC 8-KNEUTRAL 50General
Summit Therapeutics Inc. (SMMT) files 8-K
Filed: 2026-08-26 AccNo: 0001599298-26-000074 Size: 1 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
17d agoInvestorsHubBULLISH 69Product/PR
Summit Therapeutics shares rise after partner reports positive Phase III cancer trial results
Summit Therapeutics shares rise 7.75% after partner Akeso reports positive Phase III results for ivonescimab in advanced biliary tract cancer.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →